XTalks

SEPTEMBER 21, 2023

The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. This groundbreaking endeavor has received support from the National Institute of Allergy and Infectious Diseases (NIAID).

Vaccine 59

Vaccine Vaccination Trials Clinical Trials 59

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. The phase 1 study that is being run by the National Institute of Allergy and Infectious Diseases tests three dose levels of the vaccine, mRNA-1273, given in two injections a month apart in 120 adults.

Vaccine 53

Vaccine Vaccination Research Trials 53

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. About INOVIO.

DNA 40

DNA Vaccine Vaccination Immune Response 40

The Pharma Data

NOVEMBER 9, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma.

Trials 52

Trials Production Sales Manufacturing 52

Pfizer

JULY 19, 2022

The companies’ previously announced safety, tolerability and immunogenicity data from a Phase 2/3 trial that found a 30 µg booster dose of the Omicron-adapted bivalent vaccine candidate elicited a superior immune response against Omicron BA.1 is immunocompromised or are on a medicine that affects the immune system. has a fever.

Vaccine 100

Vaccine Vaccination Medicine Clinical Trials 100

The Pharma Data

SEPTEMBER 8, 2021

Rilzabrutinib is a potential first-in-class, oral Bruton’s tyrosine kinase (BTK) inhibitor in development for immune-mediated diseases. The BTK enzyme plays a key role in a number of immune processes including B cell expansion, production of immunoglobulins, and activation of innate cells such as mast cells, eosinophils, and basophils.

Trials 52

Trials Immune Response Allergies Clinical Trials 52

Pfizer

JULY 8, 2022

Following a third dose in this age group , the vaccine was found to elicit a strong immune response, with a favorable safety profile similar to placebo. IMPORTANT SAFETY INFORMATION Tell your vaccination provider about all the vaccine recipient’s medical conditions, including if the vaccine recipient: has any allergies.

Vaccine 81

Vaccine Vaccination Clinical Trials Clinical Trials 81

Pfizer

JULY 8, 2022

The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. . INTERCHANGEABILITY. IMPORTANT SAFETY INFORMATION .

FDA Approval 102

FDA Approval Vaccine Vaccination Clinical Trials 102

The Pharma Data

DECEMBER 21, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma.

Trials 40

Trials Production Sales Manufacturing 40

Pharmaceutical Technology

FEBRUARY 3, 2023

The Janssen vaccines studied in the Imbokodo and Mosaico studies were based on the mosaic concept, where they were intentionally designed to include a broader immunogen that could be used everywhere, says Dr. Mary Marovich, director of the Vaccine Research Program at National Institute of Allergy and Infectious Diseases (NIAID).

Vaccine 293

Vaccine Vaccination Antibody Trials 293

XTalks

NOVEMBER 30, 2023

to 10-fold relative to baseline within 28 days after the cell product infusion. Preclinical data demonstrated that HB-500 was well-tolerated, eliciting robust, high-quality and enduring immune responses, including antigen-specific T cells and antibodies, in non-human primates. In November 2023, Hookipa Pharma Inc.,

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

XTalks

NOVEMBER 5, 2024

Proceeds from the IPO will fund preclinical and clinical development for Polyrizon’s innovative hydrogel product candidates, supporting further research and development (R&D). Trading began on the Nasdaq Capital Market under the ticker “PLRZ” on October 29, 2024.

Drug Delivery 111

Drug Delivery Drugs Immune Response Allergies 111

pharmaphorum

FEBRUARY 28, 2021

The swift approval comes as no surprise, after the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) backed the shot unanimously at a meeting held on Friday. The vaccine causes the body to create its own copies of the protein, stimulating an immune response.

Vaccine 59

Vaccine Vaccination Immune Response Protein 59

Pfizer

NOVEMBER 2, 2022

The influenza virus is subject to constant mutations to evade the host immune response, causing a seasonal variation in circulating strains. Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. are immunocompromised or are on a medicine that affects the immune system.

Vaccine 85

Vaccine Vaccination Clinical Trials Clinical Trials 85

The Pharma Data

JANUARY 17, 2021

By inhibiting calcineurin, the drug blocks IL-2 expression and T-cell mediated immune responses. The supporting research was run in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).

Manufacturing 52

Manufacturing Immune Response Allergies Drugs 52

The Pharma Data

APRIL 28, 2021

About Rilzabrutinib Rilzabrutinib is an oral, reversible covalent, Bruton’s tyrosine kinase (BTK) inhibitor being investigated for the treatment of immune mediated diseases. BTK is involved in innate and adaptive immune responses and is a signaling molecule in immune mediated diseases.

Dermatology 40

Dermatology Trials Clinical Trials Clinical Trials 40

The Pharma Data

JANUARY 29, 2021

Emergency Use Authorization (EUA) in early February and expects to have product available to ship immediately following authorization. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at the U.S.

Vaccine 40

Vaccine Vaccination Trials Development 40

The Pharma Data

OCTOBER 26, 2020

The National Institute of Allergy and Infectious Diseases (NIAID), the study sponsor, could not verify the safety issue, but their analysis also indicated there was little likelihood the antibody would help the hospitalized patients. Eli Lilly halted a separate study of its LY-COV555 antibody against COVID-19 in hospitalized patients.

Antibody 52

Antibody Vaccine Vaccination Manufacturing 52

The Pharma Data

FEBRUARY 8, 2021

In Europe, where the product is commercially available in several countries and has a temporary license to be sold in France, sales were €12 million. Cardiovascular and Established Rx Products. Total Cardiovascular and Established Rx Products. Allergy Cough & Cold. Full-year 2020 Soliqua ® sales increased 36.1%

Sales 52

Sales Vaccine Vaccination Production 52

The Pharma Data

FEBRUARY 4, 2021

In Europe, where the product is commercially available in several countries and has a temporary license to be sold in France, sales were €12 million. Cardiovascular and Established Rx Products. Total Cardiovascular and Established Rx Products. Allergy Cough & Cold. Full-year 2020 Soliqua ® sales increased 36.1%

Sales 52

Sales Vaccine Vaccination Production 52

The Pharma Data

APRIL 27, 2021

up 60%) driven by increase disease and product awareness as well as adoption of new ISTH (International Society on Thrombosis and Haemostasis) TTP guidelines. Globally, diagnosis of the disease and product awareness remain impacted by the COVID-19 environment. . Cardiovascular and Established Rx Products. Net sales (€ million).

Sales 52

Sales Vaccine Vaccination Medicine 52

pharmaphorum

AUGUST 13, 2020

In the Philippines, Coca-Cola handed over its precious advertising space to support the COVID-19 relief and response efforts of local communities. Bacardi switched production from its famous rum to ethanol so that hand sanitiser could be manufactured in bulk. Louis Vuitton did much the same thing in France.

Branding 112

Branding Vaccine Vaccination Filler 112

XTalks

MAY 2, 2024

Some treatments already on the market have grabbed additional approvals in 2024, including Novo Nordisk’s Wegovy (semaglutide) for cardiovascular risk reduction, Dupixent (dupilumab) for eosinophilic esophagitis (EoE) in young children and Xolair (omalizumab) for food allergies.

Drugs 52

Drugs FDA Approval Vaccine Vaccination 52

XTalks

JANUARY 2, 2025

According to the companys 2023 annual report , Stelara remains its top-selling product. Despite the anticipated competition, J&J is confident its immunology drugs decline in market share will be offset by a robust pipeline of 25 potential blockbuster products. percent of J&Js total revenue for the year.

Sales 85

Sales FDA Approval Drugs Marketing 85

The Pharma Data

DECEMBER 31, 2020

The vaccine teaches the cells to make a piece of the spike protein, which triggers an immune response to help prevent illness if later exposed to the virus. These reactions can be treated, and most patients with allergies can still get the vaccine. The partial piece of the spike protein cannot cause COVID-19 disease.

Vaccine 52

Vaccine Vaccination FDA Approval Hormones 52

The Pharma Data

MAY 13, 2021

In addition, these vectors carry the genetic code of several Ebola virus proteins in order to trigger an immune response. The Ebola vaccine regimen was developed and is manufactured using Janssen’s proprietary AdVac ® technology.

Vaccine 52

Vaccine Vaccination Medicine Clinical Trials 52

pharmaphorum

JULY 26, 2022

Earlier this year , the US National Institute of Allergy and Infectious Disease (NIAID), announced that it had begun a phase 1 clinical trial evaluating three mRNA vaccines against HIV that were developed alongside Moderna. Leronlimab blocks HIV from entering immune cells due to a surface protein called CCR5.

Gene Therapy 140

Gene Therapy Protein Vaccine Vaccination 140

The Pharma Data

DECEMBER 31, 2020

20, he will he activate a law known as the Defense Production Act to “order private industry to accelerate the making of the materials needed for the vaccines as well as protective gear.” National Institute of Allergy and Infectious Diseases, Gov. Speaking Tuesday in Wilmington, Del., population.

Vaccine 52

Vaccine Vaccination Genetics Protein 52

XTalks

SEPTEMBER 14, 2020

These companies include Moderna, a US biotech company which has formed a partnership with the National Institute of Allergy and Infectious Diseases (NIAID), Oxford University who has partnered with AstraZeneca, and Johnson & Johnson, Merck and Pfizer. China’s COVID-19 Vaccine: Sinovac Biotech and CanSino Biologics.

Vaccine 92

Vaccine Vaccination Antibody Life Science 92